Merck
fights Bilharzia in Mozambique
54m treated
By Justine Wangui (ScienceAfrica
correspondent)
justinewangui@gmail.com
Merck pharmaceutical company is fighting bilharzia (schistosomiasis) worm in Mozambique, Malawi and Senegal and other African nations hoping to eliminate it by taking a holistic approach including education programs to ensure that less children contract the disease while giving them new opportunities for a brighter future.
justinewangui@gmail.com
Merck pharmaceutical company is fighting bilharzia (schistosomiasis) worm in Mozambique, Malawi and Senegal and other African nations hoping to eliminate it by taking a holistic approach including education programs to ensure that less children contract the disease while giving them new opportunities for a brighter future.
Merck
collaborates with World Health Organization (WHO) to fight and has donated more
than 200 million praziquantel tablets to treat almost 54 million
patients. WHO estimates show that over 18 million people in Mozambique
require treatment. This amounts up to four out of five people infected thus
portraying the vast spread of the epidemic. In agreement with WHO, the
country has been receiving tablets from the British Department for
International Development (DFID) since 2O11.
Currently, Merck and British Schistosomiasis Control Initiative (SCI) which are both members of the Global Schistosomiasis Alliance developing a joint concept to fight future outbreak of schistosomiasis in Mozambique. (Source:http://www.merckgroup.com)
Currently, Merck and British Schistosomiasis Control Initiative (SCI) which are both members of the Global Schistosomiasis Alliance developing a joint concept to fight future outbreak of schistosomiasis in Mozambique. (Source:http://www.merckgroup.com)